Tesamorelin Reconstitution: Measurement Education and What Studies Used

Questions about reconstituting a tesamorelin vial are, at their core, questions about arithmetic and units rather than about pharmacology. This page explains what reconstitution means as a laboratory concept, how concentration math works, how syringe graduations correspond to volumes, how to read a certificate of analysis (COA) for vial contents, and what the published clinical literature on tesamorelin administered and measured. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here states a quantity that any individual should prepare, measure or use.

What "Reconstitution" Means

Many peptides are supplied as a lyophilised powder. Lyophilisation (freeze-drying) removes water under vacuum, leaving a dry cake or film that is more chemically stable in storage than a solution. Reconstitution is simply the step of adding a sterile diluent back to that powder so the solid dissolves into a liquid of known concentration.

Three variables define the outcome of that step:

• Vial content — the mass of peptide in the vial, expressed in milligrams (mg).
• Diluent volume — the volume of sterile liquid added, expressed in millilitres (mL).
• Resulting concentration — mass divided by volume, expressed in milligrams per millilitre (mg/mL).

Nothing about reconstitution changes the total mass of peptide in the vial. Adding more diluent does not create more compound; it spreads the same mass across a larger volume, which lowers the concentration and increases the volume that would contain any given mass. That is the entire conceptual content of the operation.

The Core Arithmetic: mg ÷ mL = mg/mL

Concentration is a ratio. If a vial contains M milligrams and V millilitres of diluent are added, the concentration C is:

1. C (mg/mL) = M (mg) ÷ V (mL)
2. To go the other way — mass contained in a measured volume — the rearrangement is M = C × V.
3. To find the volume that contains a given mass, V = M ÷ C.

Those three forms are the same equation. Most confusion about reconstitution comes from mixing units mid-calculation: micrograms (µg) against milligrams, or syringe "units" against millilitres. One milligram equals 1,000 micrograms. One millilitre equals 1,000 microlitres (µL). Keeping every term in a single unit system before dividing removes almost every common error.

A Purely Arithmetic Illustration

The table below is a worked example of the division above. It is not a suggestion of vial size, diluent volume or measured amount for any person; it exists to show how the ratio behaves when the inputs change.

Reading across any row shows the invariant: the total mass in the vial never changes, only the concentration and therefore the volume associated with a given mass. PeptideU's reconstitution calculator performs exactly this division and unit conversion; it is a lab-math utility, not a recommendation engine, and it cannot know anything about an individual.

How Syringe Unit Markings Map to Millilitres

Small-volume syringes are frequently graduated in "units" rather than millilitres because they were designed around insulin standards. On a U-100 syringe, 100 units correspond to 1 mL. The conversions follow directly:

Two points are worth emphasising for anyone reading the literature. First, a "unit" on a syringe barrel is a volume marking, not a measure of peptide mass or biological activity — the mass it represents depends entirely on the concentration produced during reconstitution. Second, U-40 and U-500 syringes exist for other purposes and use different scales, so the same numeric marking on a differently scaled barrel corresponds to a different volume. Published clinical trials avoided this ambiguity by reporting amounts in milligrams of drug, not in syringe units.

Reading a COA for Vial Contents

A certificate of analysis is the document a manufacturer issues describing what analytical testing found in a given lot. For measurement purposes, several fields matter:

• Identity — usually confirmed by mass spectrometry, comparing the observed molecular mass with the theoretical mass of the stated sequence.
• Purity — typically reported as the percentage of the main peak by reversed-phase HPLC, with related substances as smaller peaks.
• Peptide content vs. net weight — a critical distinction. Lyophilised peptide powder also contains counterions (commonly acetate or trifluoroacetate), residual water and sometimes excipients such as mannitol. "Peptide content" (or "net peptide" by nitrogen analysis or amino-acid analysis) describes the fraction of the gross powder that is actually peptide, and it is often lower than the gross fill weight.
• Water content — Karl Fischer titration values indicate residual moisture, which affects both mass accounting and stability.
• Lot number and date — the COA only describes the specific lot tested; a document for a different lot describes different material.

Because of the peptide-content distinction, the labelled milligram figure and the true peptide mass are not always the same number, which means the concentration produced by any given division may differ from the nominal figure. Research-use-only materials are not required to meet the pharmaceutical release specifications that apply to approved finished products, and they are labelled for laboratory research rather than human use.

Diluents Used in Pharmaceutical Practice

In general pharmaceutical practice, lyophilised peptide powders are reconstituted with a sterile aqueous diluent. Sterile water for injection contains no preservative; bacteriostatic water for injection contains benzyl alcohol as an antimicrobial preservative; sodium chloride 0.9% is an isotonic alternative used for some products. The choice affects tonicity, preservative exposure and the in-use stability period assigned by a manufacturer, and it is specified by the product's own labelling rather than chosen arbitrarily. Peptide solutions are generally handled gently — swirled rather than shaken — because mechanical shear and foaming can promote aggregation, and they are protected from heat and light. None of this is unique to tesamorelin; it is standard handling chemistry for lyophilised peptides.

What Tesamorelin Studies Administered and Measured

The clinical literature describes tesamorelin in milligrams of drug delivered subcutaneously, which sidesteps concentration questions entirely. Early drug evaluations described tesamorelin as a synthetic analogue of human growth hormone-releasing factor developed for HIV-associated lipodystrophy (PMID 17086939), and a later review characterised it as a growth hormone-releasing factor analogue evaluated in that indication (PMID 19243281).

Reviews of the pivotal programme reported that tesamorelin 2 mg once daily by subcutaneous injection reduced visceral adipose tissue in adults with HIV-associated lipodystrophy (PMID 21668043), and a parallel review summarised the same 2 mg daily subcutaneous regimen and its effects on trunk fat and triglycerides (PMID 22050344). A pharmacotherapy review likewise described tesamorelin as a daily subcutaneous growth hormone-releasing factor analogue for excess abdominal fat in this population (PMID 22298602).

Later randomised work extended the same daily subcutaneous format to other endpoints. A randomised, double-blind, multicentre trial of tesamorelin 2 mg daily over 12 months in people with HIV and non-alcoholic fatty liver disease reported reductions in hepatic fat fraction relative to placebo (PMID 31611038). A separate analysis reported that tesamorelin improved fat quality independent of changes in fat quantity (PMID 33756511), and a targeted proteomic and transcriptomic study set out to delineate tesamorelin response pathways in HIV-associated NAFLD (PMID 34006921). Researchers also evaluated tesamorelin against neurocognitive endpoints in persons with HIV and abdominal obesity (PMID 39813152), and a further trial assessed efficacy and safety in people with HIV receiving integrase inhibitors (PMID 38905488).

For anyone trying to connect administered amounts to measured exposure, a population pharmacokinetic and pharmacodynamic analysis characterised tesamorelin concentrations after subcutaneous administration in HIV-infected patients and healthy subjects and related exposure to IGF-1 response (PMID 25895899). That analysis illustrates a point the arithmetic above cannot capture: concentration in a vial is a preparation variable, while absorption, clearance and biomarker response are biological variables measured in people under study conditions.

Tolerability in Trials: What Studies Report

Reviews of the tesamorelin development programme reported injection-site reactions, arthralgia, myalgia, peripheral oedema and paraesthesia among the more frequently observed adverse events, alongside monitoring of glucose parameters given the IGF-1-raising mechanism (PMID 21668043). A second review similarly summarised injection-site events and effects on glucose indices during tesamorelin treatment in HIV-associated lipodystrophy (PMID 22050344). A 2026 meta-analysis of randomised controlled trials pooled body composition, hepatic fat, metabolic and safety outcomes for tesamorelin in HIV-associated lipodystrophy (PMID 41545261), and the integrase-inhibitor trial reported safety outcomes in that specific population (PMID 38905488). These findings were generated under clinical trial supervision in defined patient populations and do not transfer to unsupervised settings.

What the Math Cannot Tell Anyone

Division answers exactly one question: what concentration results from a given mass and volume. It says nothing about sterility, endotoxin burden, identity, in-use stability, appropriateness for any person, or whether a given material is what its label claims. Approved tesamorelin products carry manufacturer-specified reconstitution instructions and in-use limits that are part of the approved labelling; research-use-only powders carry no such labelling and are not intended for human administration. Anyone with a clinical question about tesamorelin is directed to a licensed physician, not to a calculator.

References

• Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor (Current Opinion in Investigational Drugs, 2006)
• Tesamorelin, a human growth hormone releasing factor analogue (Expert Opinion on Investigational Drugs, 2009)
• Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (Drugs, 2011)
• Spotlight on tesamorelin in HIV-associated lipodystrophy (BioDrugs, 2011)
• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (The Annals of Pharmacotherapy, 2012)
• Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects (Journal of Pharmacokinetics and Pharmacodynamics, 2015)
• Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial (The Lancet HIV, 2019)
• Tesamorelin improves fat quality independent of changes in fat quantity (AIDS, 2021)
• Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach (Scientific Reports, 2021)
• Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (AIDS, 2024)
• Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity (The Journal of Infectious Diseases, 2025)
• Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials (Obesity Research & Clinical Practice, 2026)